|1.||Paus, Elisabeth: 10 articles (07/2014 - 01/2007)|
|2.||Reubsaet, Léon: 7 articles (12/2014 - 09/2009)|
|3.||Stieber, Petra: 7 articles (08/2012 - 09/2006)|
|4.||Nordlund, Marianne S: 6 articles (05/2015 - 01/2007)|
|5.||Molina, Rafael: 5 articles (01/2015 - 01/2004)|
|6.||Holdenrieder, Stefan: 5 articles (01/2015 - 09/2006)|
|7.||Patel, Oneel: 4 articles (05/2015 - 01/2006)|
|8.||Baldwin, Graham S: 4 articles (05/2015 - 01/2006)|
|9.||Shulkes, Arthur: 4 articles (05/2015 - 01/2006)|
|10.||Halvorsen, Trine Grønhaug: 4 articles (12/2014 - 09/2009)|
|1.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/01/2007 - "Monitoring serum ProGRP levels, followed by whole-body FDG-PET when indicated, may improve the clinical management of patients with small-cell lung cancer after initial complete remission."
06/01/2011 - "All published studies on ProGRP in the diagnosis of small cell lung cancer from January 1994 to April of 2010 were retrieved. "
06/01/2011 - "The aim of this study was to systematically evaluate ProGRP as the diagnostic standard for small cell lung cancer. "
05/01/2009 - "The objective of this study was to develop a method using liquid chromatography with tandem mass spectrometric detection for the absolute quantification of the small cell lung cancer biomarker ProGRP in human serum, using its tryptic signature peptide NLLGLIEAK. "
01/01/2009 - "Studies on multiple forms of proGRP in serum from small cell lung cancer patients."
01/01/2003 - "After tumor remission the NSE but also the ProGRP levels decreased significantly under treatment (p=0.0001 resp. "
01/01/2010 - "The presented study revealed that ProGRP is a tumor marker of choice in SCLC, because of its high diagnostic specificity in relation to the reference group and to the group with other malignancies."
01/01/2010 - "The aim of this study was to assess the utility of ProGRP determinations in patients with selected cancer localization, during and after therapy. "
01/01/2014 - "In conclusion, ProGRP should be further evaluated as biomarker in a larger series of patients to determine whether it demonstrates any significant correlation with cancer recurrence."
01/01/2014 - "The serum tumor marker, the ProGRP level, was significantly elevated (161 ng/ml). "
|3.||Lung Neoplasms (Lung Cancer)
11/01/2012 - "Since the present case showed a mild impairment of renal function, it was suggested that the cause of the high level of ProGRP was other than lung cancer."
12/01/2011 - "To determine the clinicopathological features of NSCLC in patients with elevated serum proGRP concentrations, serum proGRP values were assessed in 654 advanced lung cancer patients, and positive (>46pg/mL) NSCLC specimens were subjected to cytological and histopathological reevaluation. "
12/01/2010 - "The sensitivity of CEA, CA125, CYFRA21-1, TPA, SCCAg, DKK1, NSE, ProGRP in the patients' serum with lung cancer were 47.50%, 50.11%, 57.00%, 50.93%, 49.00%, 69.50%, 39.73%, 51.48% and the specificity were 92.34%, 80.19%, 90.16%, 88.41%, 91.07%, 92.20%, 89.11%, 94.89%. "
11/01/2009 - "The diagnostic and prognostic value of ProGRP in lung cancer."
07/01/2004 - "ProGRP serum levels are clearly related to the lung cancer histological type with significantly higher levels observed in SCLC than in nonsmall cell lung cancer (NSCLC). "
|4.||Lung Diseases (Lung Disease)
09/01/2000 - "Assessing the sensitivity in the SCLC population and the specificity in benign lung disease, ProGRP demonstrated the best sensitivity relationship in as much as its AUC-ROC was significantly greater than the ones calculated using NSE and CGA (respective values, 0.95, 0.89, 0.70; two-tailed Z-test <0.05). "
05/01/2011 - "This study evaluated the agreement between proGRP levels in fresh serum and plasma in patients with various lung diseases. "
05/01/2010 - "The best diagnostic profile in SCLC versus benign lung diseases was observed for NSE (AUC 93.9%) and ProGRP (AUC 85.4%), while TK did not have any diagnostic power (AUC 46.6%). "
04/01/1995 - "In contrast, the frequency of increased serum ProGRP(31-98) in patients with nonmalignant pulmonary diseases or non-SCLC was quite low: 0% and 5.0%, respectively. "
04/15/1994 - "Serum levels of immunoreactive ProGRP(31-98) were measured in 247 normal subjects, 180 patients with nonmalignant pulmonary diseases, 231 patients with non-SCLC, and 140 patients with SCLC. "
|5.||Pleural Effusion (Pleural Effusions)
01/01/2008 - "The diagnostic value of pleural effusion ProGRP, NSE, CYFRA21-1, CEA, CA153 and CA19-9 was compared for each group. "
06/20/2006 - "In the SCLC group, detection of pleural effusion ProGRP showed the highest Youden index and accuracy. "
06/20/2006 - "The levels of ProGRP, NSE, CYFRA21-1 and CEA in serum and pleural effusion of all the malignant groups were significantly higher than those in the control groups (P < 0.01). "
06/20/2006 - "Diagnostic value of serum and pleural effusion ProGRP , NSE, CYFRA21-1 and CEA was evaluated for each group. "
01/01/1996 - "The determination of ProGRP(31-98) in pleural effusions will be helpful for diagnosing carcinomatous pleurisy due to SCLC."
|2.||Etoposide (VP 16)
|4.||Biological Tumor Markers (Tumor Markers)
|5.||Protein Isoforms (Isoforms)
|10.||Phosphopyruvate Hydratase (Enolase)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Drug Therapy (Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)